Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Parallel Advisors LLC

Parallel Advisors LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 32,064 shares of the medical research company’s stock after acquiring an additional 750 shares during the quarter. Parallel Advisors LLC’s holdings in Thermo Fisher Scientific were worth $17,731,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in TMO. SYM FINANCIAL Corp grew its stake in Thermo Fisher Scientific by 14.0% during the 2nd quarter. SYM FINANCIAL Corp now owns 710 shares of the medical research company’s stock worth $393,000 after buying an additional 87 shares during the last quarter. GHP Investment Advisors Inc. raised its holdings in shares of Thermo Fisher Scientific by 50.4% in the second quarter. GHP Investment Advisors Inc. now owns 5,146 shares of the medical research company’s stock valued at $2,846,000 after buying an additional 1,724 shares during the last quarter. TradeLink Capital LLC purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth about $608,000. Meeder Advisory Services Inc. lifted its position in Thermo Fisher Scientific by 37.1% during the 2nd quarter. Meeder Advisory Services Inc. now owns 7,410 shares of the medical research company’s stock worth $4,098,000 after acquiring an additional 2,005 shares during the period. Finally, DekaBank Deutsche Girozentrale grew its stake in shares of Thermo Fisher Scientific by 6.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 819,893 shares of the medical research company’s stock valued at $450,892,000 after purchasing an additional 52,675 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.4 %

NYSE:TMO opened at $611.17 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $627.88. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The company has a market cap of $233.47 billion, a PE ratio of 39.20, a P/E/G ratio of 2.88 and a beta of 0.78. The business’s 50 day moving average is $592.10 and its two-hundred day moving average is $580.06.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm’s revenue was down 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $5.15 earnings per share. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Wells Fargo & Company assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price objective on the stock. Raymond James lifted their target price on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Robert W. Baird lifted their price target on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Barclays reduced their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $630.41.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,084 shares of company stock worth $14,094,292. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.